{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:03Z","timestamp":1753891203488,"version":"3.41.2"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of non-Hodgkin lymphoma with a good prognosis, but the optimal treatment for relapsed\/refractory (R\/R) SPTCL has been rarely discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study aims to compare the efficacy of conventional chemotherapy and chemo-free immunomodulatory regimen for R\/R SPTCL. We retrospectively reviewed the patients with first relapse or primary refractory SPTCL between September 1997 and October 2020.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 19 patients with R\/R SPTCL with a median age of 34 were included. All patient received the first-line chemotherapy-based treatment with a median PFS of 1.8 months. In these patients, 16 received salvage second-line treatment with an ORR of 31.3% and a median TTNT of 3.0 months. 13 of these 16 patients received chemotherapy-based treatment, resulting in a median TTNT of 2.4 months. 2 of these 16 patients received allogeneic hematopoietic stem cell transplantation and achieved long term complete remission (CR). In third-line treatment, 7 patients received chemotherapy-based regimen and 6 received chemo-free regimen such as VRMP (bortezomib, lenadomide and methylprednisolone) regimen and CsA plus IFN\u03b1 regimen. The median TTNT of chemotherapy and chemo-free group were 3.2 months and not reached, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Chemo-free group had a better TTNT than chemotherapy group (p=0.007). The use of chemotherapy-free regimens for R\/R SPTCL appears promising and warrants further validation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1476875","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T06:30:20Z","timestamp":1733725820000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed\/refractory subcutaneous panniculitis-like T-cell lymphoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Chao","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daobin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1684\/ejd.2016.2914","article-title":"Clinical characteristics, differential diagnosis, and treatment outcome of subcutaneous panniculitis-like T-cell lymphoma: a literature review of published Japanese cases","volume":"27","author":"Ohtsuka","year":"2017","journal-title":"Eur J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2011.23.3.329","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: a clinical and pathologic study of 14 korean patients","volume":"23","author":"Lee","year":"2011","journal-title":"Ann Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31817a9081","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathologic, immunophenotypic, and molecular study of 22 Asian cases according to WHO-EORTC classification","volume":"32","author":"Kong","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3347","article-title":"Clinical and pathological characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma and related adipotropic lymphoproliferative disorders","volume":"158","author":"Guitart","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"20587384211009342","DOI":"10.1177\/20587384211009342","article-title":"Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review","volume":"35","author":"Li","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i8.1885","article-title":"Subcutaneous panniculitis-like T-cell lymphoma invading central nervous system in long-term clinical remission with lenalidomide: A case report","volume":"9","author":"Sun","year":"2021","journal-title":"World J Clin cases"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.2018.181.issue-3","article-title":"Recurrent mutations in epigenetic modifiers and the PI3K\/AKT\/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma","volume":"181","author":"Li","year":"2018","journal-title":"Br J Haematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2615-0","article-title":"Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review","volume":"95","author":"Chen","year":"2016","journal-title":"Ann Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.193909","article-title":"Subcutaneous panniculitis-like T-cell lymphoma with macrophage activation syndrome treated by cyclosporine and prednisolone","volume":"7","author":"Asati","year":"2016","journal-title":"Indian Dermatol Online J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1259\/bjr\/69172676","article-title":"Subcutaneous panniculitis-like T-cell lymphoma with breast involvement: functional and morphological imaging findings","volume":"83","author":"Schramm","year":"2010","journal-title":"Br J Radiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"201836","DOI":"10.1155\/2014\/201836","article-title":"Successful treatment of disseminated subcutaneous panniculitis-like T-cell lymphoma with single agent oral cyclosporine as a first line therapy","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Case Rep Dermatol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2932","article-title":"A case of refractory subcutaneous panniculitis-like T-cell lymphoma with bone marrow and lung involvement treated successfully with oral etoposide","volume":"98","author":"Saito","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/cup.2015.42.issue-1","article-title":"Systemic panniculitis-like T-cell lymphoma with involvement of mesenteric fat and subcutis","volume":"42","author":"Lester","year":"2015","journal-title":"J Cutan Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.965142","article-title":"Bortezomib for the treatment of non-Hodgkin\u2019s lymphoma","volume":"15","author":"Bose","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402610","article-title":"Bortezomib inhibits expression of TGF-beta1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells","volume":"194","author":"Chang","year":"2015","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.09.002","article-title":"Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease","volume":"60","author":"Broccoli","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt242","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","author":"Willemze","year":"2013","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1476875\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T06:30:24Z","timestamp":1733725824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1476875\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2024.1476875"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1476875","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"article-number":"1476875"}}